BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.75 | 0.38 | 0.39 | 1.59 |
| FCF Yield | 3.27% | 1.60% | 1.17% | 1.32% |
| EV / EBITDA | -1,853.75 | 31.07 | 49.63 | 62.37 |
| Quality | ||||
| ROIC | -0.80% | 3.30% | 2.68% | 1.86% |
| Gross Margin | 81.95% | 81.82% | 79.66% | 81.78% |
| Cash Conversion Ratio | -11.99 | 0.43 | 0.94 | 1.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.22% | 11.09% | 10.73% | 10.84% |
| Free Cash Flow Growth | 102.32% | 6.69% | -4.66% | -17.46% |
| Safety | ||||
| Net Debt / EBITDA | 124.28 | -1.91 | -1.70 | -1.74 |
| Interest Coverage | -18.10 | 103.35 | 78.20 | 62.63 |
| Efficiency | ||||
| Inventory Turnover | 0.10 | 0.11 | 0.12 | 0.11 |
| Cash Conversion Cycle | 729.29 | 710.57 | 671.89 | 738.82 |